"JPMorgan sees upside to consensus estimates and AbbVie's own guidance, even after the company revised its full-year adjusted diluted EPS outlook to $13.96 to $14.16 following a $744 million pre-tax IPR&D charge."
"Skyrizi generated $5.01 billion in Q4 2025 revenue, up 32.5% year over year, while Rinvoq posted $2.37 billion, up 29.5%. The immunology segment as a whole grew 18.3% year over year to $8.63 billion in Q4."
"Humira continues to face biosimilar erosion, declining 25.9% year over year in Q4 to $1.25 billion. The neuroscience segment is picking up meaningful slack, growing 17.9% to $2.96 billion in Q4."
AbbVie stock has decreased by 12% recently, prompting JPMorgan to maintain an Overweight rating and a $260 price target. Investor sentiment has turned negative due to competition from Johnson & Johnson. However, JPMorgan believes current share levels present an attractive opportunity ahead of AbbVie's Q1 report. The firm anticipates upside to consensus estimates, supported by strong growth in Skyrizi and Rinvoq. AbbVie reported record revenues of $61.16 billion in 2025, despite challenges from biosimilars affecting Humira sales.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]